MacroGenics
Rockville, Maryland, United States · Biopharma, Biotechnology, Health Care
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. They have a strong emphasis on creating novel and differentiated oncology product candidates.
Key facts
- Headquarters
- Rockville, Maryland, United States
- Employees
- 350
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (MGNX)
- Website
- macrogenics.com
- Company page
Recent activity at MacroGenics
- : SEC 8-K (7.01): On November 13, 2026, MacroGenics, Inc. provided an updated corporate presentation on its website, detailing new clinical program information. This disclosure is categorized under Regulation FD, which emphasizes that the information is not to be considered 'filed' with the SEC for purposes of Section 18 of the Securities Exchange Act. The relevant corporate presentation, attached as Exhibit 99.1, showcases important updates that may impact stakeholder understanding and engagement with the company's clinical developments.
- : SEC 8-K (5.02): On October 30, 2026, MacroGenics, Inc.'s Board of Directors approved an increase in the board size from ten to eleven members. The Board appointed Michael Vasconcelles as a Class II Director and Emil Kuriakose as a Class III Director, both of whom are deemed independent under Nasdaq and Securities Exchange Act standards. Their terms will last until the 2027 and 2028 annual meetings of stockholders, respectively. Both directors will receive annual retainers and equity awards, including options to purchase 44,000 shares and RSUs for 7,500 shares each, under the Company’s 2023 Equity Incentive Plan. This appointment is seen as a strategic move to enhance board expertise and governance.
- : SEC 8-K (8.01): On October 23, 2026, MacroGenics, Inc. announced interim data related to its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate for patients with advanced solid tumors. This announcement includes a poster presentation at the European Society for Medical Oncology Congress in Madrid, taking place from October 23-27, 2026. The Company also posted a slide presentation titled 'MGC026 Clinical Update (ESMO)' on its website, providing further information regarding the study. The developments indicate the Company’s ongoing commitment to advancing cancer treatment options and may attract investor interest based on promising research findings.
- : SEC 8-K (8.01): On July 23, 2026, MacroGenics, Inc. provided a clinical update regarding its ongoing Phase 1 study of MGC026. The press release, attached as Exhibit 99.1, highlights new findings and developments in the clinical trial, which has implications for the company's ongoing research and potential product pipeline. This update may influence investor sentiment and market perception of MacroGenics' clinical progress and future prospects. The event date, July 23, 2026, indicates timely dissemination of significant information to shareholders and stakeholders.
- : SEC 8-K (5.02):
- : SEC 8-K (2.01):
- : SEC 8-K (1.01): On May 11, 2026, MacroGenics, Inc. entered into a Material Definitive Agreement with Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC, to sell its GMP manufacturing operations, particularly its CDMO business, for $122.5 million in cash at closing, with potential additional payments of up to $5 million based on certain milestones. The sale includes assets and current liabilities related to the CDMO Operations at their facilities in Maryland, while excluding research-related resources. The transaction is expected to close in the third quarter of 2026, following the satisfaction of closing conditions, and will be accompanied by various ancillary agreements for continued service support between the parties. This represents a significant strategic shift for MacroGenics, streamlining its focus while generating substantial immediate cash flow.
- : SEC 8-K (1.01): On May 1, 2026, MacroGenics, Inc. entered into a First Amendment to the Royalty Purchase Agreement with Sagard Healthcare Partners, resulting in an additional cash payment of $60.0 million, raising the total purchase price to $130.0 million. This amendment adjusts the royalty terms, allowing royalty rights to revert back to MacroGenics after Sagard receives payments of 1.70x or 2.0x the total purchase price. Additionally, MacroGenics can earn a milestone payment of up to $20.0 million based on 2026 sales thresholds. The filing pertains to significant strategic adjustments regarding royalty payments and rights relating to the drug ZYNYZ.
- : SEC 8-K (8.01): On April 8, 2026, MacroGenics, Inc. announced via press release that the U.S. Food and Drug Administration has lifted the partial clinical hold on its Phase 2 LINNET study. This study involves lorigerlimab, an investigational bispecific DART® molecule aimed at treating patients with gynecologic cancers, thus allowing the continuation and potential expansion of the clinical trials for this drug. The removal of the hold is significant as it enables the company to proceed with patient recruitment and advancement of the study, which may have important implications for both clinical development and the company's stock performance.
- : SEC 8-K (8.01): On April 8, 2026, MacroGenics, Inc. announced via press release that the U.S. FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational bispecific DART® molecule designed to target PD-1 and CTLA-4 in patients suffering from gynecologic cancers. This development is significant as it allows the continuation of trials for a promising cancer treatment, potentially expediting the process of bringing this drug to market. The event occurred on the same date as the filing, indicating timely reporting of important regulatory news for the company. The removal of the hold is a crucial step in advancing the study, reflecting the FDA's confidence in the safety and effectiveness of the investigational drug. A copy of the press release is attached as Exhibit 99.1.
Leadership
- Eric Risser, Chief Executive Officer
Verified email and direct lines for MacroGenics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
MacroGenics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
MacroGenics in the news
- MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals - GlobeNewswire (May 11, 2026)
- Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study - BioSpace (Feb 25, 2026)
- MacroGenics closes solid tumor clinical trial after 7 people die - Fierce Biotech (Jul 11, 2022)
- MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - Seeking Alpha (Sep 09, 2026)
- MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement - Yahoo Finance (May 04, 2026)
- Janssen drops MacroGenics cancer candidate over safety concerns - BioPharma Dive (Sep 01, 2017)
- MacroGenics' stock crashes after 5 deaths in ADC trial - Fierce Biotech (May 10, 2024)
- MacroGenics switches horses in CD123 race, canning flotetuzumab in favor of next-gen successor - Fierce Biotech (Feb 25, 2022)
Companies similar to MacroGenics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Contineum Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About MacroGenics: questions and answers
What does MacroGenics do?
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. They have a strong emphasis on creating novel and differentiated oncology product candidates.
Where is MacroGenics headquartered?
MacroGenics is headquartered in Rockville, Maryland, United States.
How many employees does MacroGenics have?
MacroGenics has about 350 employees.
Who leads MacroGenics?
Eric Risser is a Chief Executive Officer at MacroGenics.
What is the latest news on MacroGenics?
On Nov 13, 2026, SEC 8-K (7.01): On November 13, 2026, MacroGenics, Inc. provided an updated corporate presentation on its website, detailing new clinical program information. This disclosure is categorized under Regulation FD, which emphasizes that the information is not to be considered 'filed' with the SEC for pu
Is MacroGenics a public company?
Yes. MacroGenics is publicly traded under the ticker MGNX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy